SenseTime Launches SenseCare Smart Health Platform, Deepening Comprehensive Clinical Workflow Integration

(September 19, Shanghai) At the “Friend of AI, Commitment to Health” Forum on Intelligent Medical Innovation and Development during the 2018 World Artificial Intelligence Conference, SenseTime officially unveiled its smart healthcare strategy and its first medical AI product prototype—the SenseCare Intelligent Diagnosis and Treatment Platform.

According to VCBeat (WeChat Official Account: vcbeat), as a globally leading artificial intelligence platform company, SenseTime has officially unveiled its medical strategic plan and products for the first time since announcing the establishment of its Smart Healthcare Laboratory in New Jersey, USA, last month. At the event, Zhang Shaoting, Vice President of SenseTime and Deputy Dean of the SenseTime Research Institute, stated that only by starting from clinical needs and using AI to empower the complete “diagnosis-treatment-recovery” workflow can the value of AI technology be fully leveraged to address the practical pain points encountered by physicians in their work.

The SenseTime Smart Healthcare team comprises numerous senior scientists and medical experts with extensive experience in the research and development of medical AI technologies. Leveraging years of deep engagement in the healthcare sector and profound insights into real-world clinical challenges, the team recognizes that beyond diagnosis, physicians face significant pain points in areas such as treatment planning and implementation, therapeutic outcome prediction, and rehabilitation assessment. These tasks are often time-consuming and labor-intensive, yet they align perfectly with scenarios where AI technology can provide effective solutions.

Against this backdrop, the Smart Healthcare team leverages SenseTime’s cutting-edge AI expertise as its technological foundation to transform proprietary AI algorithms into a comprehensive solution capable of addressing diverse clinical needs—the SenseCare Intelligent Diagnosis and Treatment Platform.

Developed on SenseTime’s proprietary deep learning platform, this algorithm possesses complete independent intellectual property rights. It is designed to cover multiple departments, including orthopedics, pulmonology, radiation oncology, neurology, and cardiology, empowering various workflows from diagnosis to treatment planning, consumable design, and surgical tracking and prediction. This comprehensive support helps physicians enhance both work efficiency and precision. Furthermore, the platform boasts robust performance capabilities: it not only supports a larger number of concurrent users accessing the system across diverse devices under specific computational resources but also allows for the customization of complex post-processing functions tailored to various clinical specialties. Notably, the platform’s architectural design meets hospitals’ stringent requirements for data security while ensuring the absolute safety of patient information.

The SenseTime Smart Healthcare Team believes that the complexity of medical issues and the rigorous nature of the healthcare industry mean that the path for medical AI is long and arduous. Each niche area requires years, or even decades, of dedicated effort, demanding the patience to overcome technical challenges one by one, solid accumulation of professional domain knowledge, and long-term close collaboration between technical teams and medical expert teams. Relying solely on the capabilities of a single team is insufficient to conduct robust exploration across multiple directions.

Based on this, SenseTime has adopted a “co-creation” strategy in its R&D layout across different fields. For instance, in orthopedics, it collaborates with top Chinese expert teams—specifically, the team led by Academician Dai Kerong and Deputy Director Ai Songtao from Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine. In the field of radiotherapy, it partners with Mednovate, which has 14 years of in-depth experience, mastering core accelerator interface technologies and possessing a complete radiotherapy product portfolio. Through such deep collaborations, SenseTime empowers traditional medical enterprises with leading original AI capabilities and develops AI tools that address actual clinical pain points. Meanwhile, these joint efforts foster a new ecosystem in medical AI and promote upstream and downstream development, thereby driving the “intelligent” transformation of the traditional healthcare industry.

In response, Zhang Shaoting stated, “Under the new strategic layout of the healthcare industry, SenseTime will further leverage its advantages in original technologies to conduct multi-dimensional explorations into the pain points and challenges across various clinical specialties. We aim to drive industrial breakthroughs through innovative technologies, foster an industrial ecosystem based on our platform, and work with partners to accelerate the comprehensive transformation of the smart healthcare industry. Meanwhile, we look forward to welcoming more professional partners to join this collaborative effort.”

In addition to collaborating with hospitals and healthcare enterprises, SenseTime has also made strategic investments across the upstream and downstream of the medical industry. In June this year, it invested in Helian Health, a company focused on the internet healthcare sector, gradually building a comprehensive “Healthcare + AI” ecosystem.